Payment overview · 2025
General Payments
$1,506.96
69 reported records · 20 companies
Healthcare provider profile · identity verified
Noel Lopez, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MCALLEN, TX · NPI 1831119908
Verified facts
What the public records show
CMS Open Payments records show Noel Lopez, M.D. received $1,506.96 in general payments during 2025 across 69 reported records.
Inspire Medical Systems, Inc. accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $405.39 | 26.9% | 14 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $206.06 | 13.7% | 9 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $101.18 | 6.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $99.60 | 6.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $91.67 | 6.1% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.37 | 5.3% | 4 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $71.23 | 4.7% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $69.71 | 4.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.35 | 4.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.95 | 3.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.86 | 3.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.97 | 2.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $34.64 | 2.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $28.30 | 1.9% | 2 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $24.41 | 1.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.53 | 1.6% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $20.31 | 1.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.28 | 1.1% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $16.56 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.59 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,506.96 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $405.39 | 14 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $206.06 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $112.85 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $101.18 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $71.63 | 3 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $71.23 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $69.71 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.95 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.80 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.86 | 3 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $46.74 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $42.97 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.87 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $34.64 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.87 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $28.30 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.97 | 2 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 138 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 147 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
138 | 37 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
147 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 534 | 176 |
| Metoprolol Succinate | Metoprolol Succinate | 523 | 179 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 469 | 166 |
| Levothyroxine Sodium | Levothyroxine Sodium | 343 | 111 |
| Alprazolam | Alprazolam | 330 | 63 |
| Losartan Potassium | Losartan Potassium | 302 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 272 | 98 |
| Lisinopril | Lisinopril | 263 | 79 |
| Metformin Hcl | Metformin Hcl | 214 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 209 | 77 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 208 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 200 | 34 |
| Omeprazole | Omeprazole | 198 | 71 |
| Montelukast Sodium | Montelukast Sodium | 177 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 60 |
| Gabapentin | Gabapentin | 159 | 56 |
| Tramadol Hcl | Tramadol Hcl | 159 | 39 |
| Ozempic | Semaglutide | 147 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 146 | 54 |
| Farxiga | Dapagliflozin Propanediol | 138 | 37 |
| Simvastatin | Simvastatin | 117 | 36 |
| Furosemide | Furosemide | 110 | 37 |
| Raloxifene Hcl | Raloxifene Hcl | 110 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 17 |
| Metformin Hcl Er | Metformin Hcl | 93 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 36 |
| Januvia | Sitagliptin Phosphate | 87 | 30 |
| Lorazepam | Lorazepam | 86 | 16 |
| Eliquis | Apixaban | 82 | 24 |
| Sertraline Hcl | Sertraline Hcl | 79 | 26 |
| Pregabalin | Pregabalin | 74 | 20 |
| Dutasteride | Dutasteride | 72 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 29 |
| Mounjaro | Tirzepatide | 68 | 14 |
| Naproxen | Naproxen | 66 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 21 |
| Ezetimibe | Ezetimibe | 61 | 25 |
| Donepezil Hcl | Donepezil Hcl | 57 | 21 |
| Tresiba Flextouch U-200 | Insulin Degludec | 55 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 53 | 31 |
| Trazodone Hcl | Trazodone Hcl | 53 | 19 |
| Celecoxib | Celecoxib | 51 | 20 |
| Mirtazapine | Mirtazapine | 50 | 16 |
| Alendronate Sodium | Alendronate Sodium | 49 | 20 |
| Buspirone Hcl | Buspirone Hcl | 48 | 14 |
| Potassium Chloride | Potassium Chloride | 48 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 13 |
| Jardiance | Empagliflozin | 46 | 15 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 46 | 16 |
| Carvedilol | Carvedilol | 45 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 17 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Valsartan | Valsartan | 43 | 14 |
| Fenofibrate | Fenofibrate | 41 | 14 |
| Spironolactone | Spironolactone | 40 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 39 | 11 |
| Linzess | Linaclotide | 39 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 39 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 17 |
| Baclofen | Baclofen | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | 15 |
| Allopurinol | Allopurinol | 34 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 12 |
| Bupropion Xl | Bupropion Hcl | 33 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 21 |
| Trulicity | Dulaglutide | 32 | 12 |
| Glimepiride | Glimepiride | 31 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 29 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 22 |
| Meloxicam | Meloxicam | 29 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | 11 |
| Cefdinir | Cefdinir | 27 | 27 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 26 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | 12 |
| Finasteride | Finasteride | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 13 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Prolia | Denosumab | 17 | 12 |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Clonidine | Clonidine | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 14 |
| Lactulose | Lactulose | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Forteo | Teriparatide | 12 | suppressed |
| Klonopin | Clonazepam | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,506.96 · 69 records | Inspire Medical Systems, Inc. | AUSTEDO XR, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE, Fluad, Flucelvax, Grastek, INJECTAFER, INSPIRE, ImmunoCAP, JARDIANCE, Korlym, LINZESS, MOUNJARO, Odactra, Omnipod, Ozempic, Ragwitek, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error